Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy-Reference-Cited by-同舟云学术

Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy

Published:2017-08-02 Issue:2 Volume:179 Page:272-283
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kuhlen Michaela¹^ORCID,Bleckmann Kirsten²,Möricke Anja²,Schrappe Martin²,Vieth Simon²,Escherich Gabriele³,Bronsema Annika³,Vonalt Annika⁴,Queudeville Manon⁴,Zwaan C. Michel⁵,Ebinger Martin⁴^ORCID,Debatin Klaus-Michael⁶,Klingebiel Thomas⁷,Koscielniak Ewa⁸,Rossig Claudia⁹,Burkhardt Birgit⁹^ORCID,Kolb Reinhard¹⁰,Eckert Cornelia¹¹,Borkhardt Arndt¹,von Stackelberg Arend¹¹,Chen-Santel Christiane¹¹

Affiliation:

1. Department of Paediatric Oncology, Haematology and Clinical Immunology; University Children's Hospital, Medical Faculty, Heinrich Heine University; Duesseldorf Germany

2. Department of Paediatrics; University Hospital Schleswig-Holstein; Kiel Germany

3. Clinic of Paediatric Haematology and Oncology; Medical Centre; Hamburg-Eppendorf Germany

4. Department of General Paediatrics, Oncology/Haematology; University Children's Hospital; Tuebingen Germany

5. Department of Paediatric Oncology/Haematology; Erasmus MC-Sophia Children's Hospital; Rotterdam the Netherlands

6. Department of Paediatrics and Adolescent Medicine; University Medical Centre; Ulm Germany

7. Department of Paediatrics; University Hospital; Frankfurt Germany

8. Department of Paediatric Oncology, Haematology and Immunology; Klinikum Stuttgart; Olgahospital Germany

9. Paediatric Haematology and Oncology; University Children′s Hospital Muenster; Muenster Germany

10. Department of General Paediatrics, Haematology/Oncology; Klinikum Oldenburg Germany

11. Department of Paediatric Oncology, Haematology; BMT, Charité University Medicine; Berlin Germany

Funder

Seventh Framework Programme

Deutsche Kinderkrebsstiftung

Jose Carreras Leukämie Stiftung

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14877/fullpdf

Reference27 articles.

1. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group;Berg;Journal of Clinical Oncology,2005

2. Treatment of childhood T-cell lymphoblastic lymphoma-long-term results of the SFOP LMT96 trial;Bergeron;Pediatric Blood & Cancer,2015

3. Nelarabine: a novel purine antimetabolite antineoplastic agent;Buie;Clinical Therapeutics,2007

4. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group;Burkhardt;Journal of Clinical Oncology,2009

5. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma;Cohen;Oncologist,2008

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols;Leukemia Research;2024-09

2. Divine noni's protective impact on Swiss albino mice's short-term memory impairment caused by cyclophosphamide: A behavioral and biochemical approach;Heliyon;2024-09

3. PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL;npj Precision Oncology;2024-07-20

4. Irbesartan mitigates the impact of cyclophosphamide-induced acute neurotoxicity in rats: Shedding highlights on NLRP3 inflammasome/CASP-1 pathway-driven immunomodulation;International Immunopharmacology;2024-06

5. Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases;International Journal of Hematology;2023-01-27